<DOC>
	<DOCNO>NCT00903838</DOCNO>
	<brief_summary>This multicenter , randomize , double blind , pramipexole-controlled parallel group study pardoprunox adjunctive treatment levodopa .</brief_summary>
	<brief_title>A Pilot Study Assess Efficacy Safety Pardoprunox Adjunct Therapy L-dopa Treatment Patients With Parkinson 's Disease Experiencing Motor Fluctuations Dyskinesia .</brief_title>
	<detailed_description>Approximately 44 patient randomize 3:1 ratio two possible treatment group , pardoprunox pramipexole , respectively . The first part study blind consist minimum 1-week screening period , 4-week switch stabilization period 8-week maintenance period . The second part study open label pardoprunox treatment dose adjustment period 4 week follow long term maintenance treatment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion Criteria Patients sign informed consent Diagnosis idiopathic Parkinson 's Disease Stable treatment Ldopa dopamine agonist least 28 day prior randomization Presence recognizable ON OFF state ( motor fluctuation ) Minimum hour OFFtime per day 1.5 hour ( wake hour include early morning akinesia ) record per baseline diary Minimum hour ON time troublesome dyskinesia 2 hour ( wake hour ) record per baseline diary Prevalent expression severely disable dyskinesias wake day , i.e . dyskinesias present least 25 % waking hour ( UPDRS Part 4 item 32 &gt; = 2 ) combination degree disability moderate high ( UPDRS Part 4 item 33 &gt; =2 ) Exclusion Criteria Diagnosis unclear suspicion parkinsonian syndromes Patients undergone surgery treatment PD</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Parkinson 's disease</keyword>
</DOC>